A Multi-center, Open-label, Extension Study to Evaluate the Long-term Safety and Efficacy of DWP16001 in Patients With Type 2 Diabetes Mellitus
Latest Information Update: 08 Oct 2024
At a glance
- Drugs Enavogliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Daewoong Pharmaceutical
Most Recent Events
- 01 Oct 2024 Results evaluating the long term safety and efficacy of DWP16001 published in the Diabetes, Obesity and Metabolism.
- 23 Oct 2022 Status changed from active, no longer recruiting to completed.
- 23 May 2022 New trial record